Prime Editing for p47 phox -Deficient Chronic Granulomatous Disease, 2025, Gori et al

Mij

Senior Member (Voting Rights)
B.C. man cured of rare disease in world-first for new gene-editing technology

Sperle is the first person known to have received and be cured by a treatment known as “prime editing,” in a breakthrough by U.S.-based Prime Medicine reported in the peer-reviewed New England Journal of Medicine last December.

“People with this disease don’t live long and healthy lives,” Turvey says.

But the sequencing of the human genome has allowed researchers to identify “spelling” mistakes in people’s DNA, he says, and “the era we’re really in now is about translating those fundamental discoveries to helping patients.”

"The gene-editing treatment involved extracting Sperle’s own cells, fixing the “spelling mistake” and inserting the cells back into his body, where they multiplied, overriding his cells that hadn’t been working properly, Turvey says.

“What that meant was, you know, his body wasn’t going to reject those cells, those cells weren’t going to attack his body because they were his cells, just fixed up.”
 
Last edited by a moderator:
Prime Editing for p47 phox -Deficient Chronic Granulomatous Disease, 2025, Gori et al

Prime Editing for p47 phox -Deficient Chronic Granulomatous Disease

Gori, Jennifer L.; Haddad, Elie; Frangoul, Haydar; Kohn, Donald B.; Morris, Emma C.; Martin, Bradley N.; Deary, Briana A.; Nickerson, McKinley; Scholz, Rebecca L.; Fernandez, Isabel; Leveille, Karine; De Ravin, Suk See; Kang, Elizabeth M.; Pierzynski, Marie; Estwick, Tyra; Littel, Patricia; Kuhns, Douglas B.; Long Priel, Debra A.; Teira, Pierre; Turvey, Stuart; Arnold, Jordyn; Evans, Misty D.; McManus, Meghann; Carpenter, Ben; Waterman, David P.; Anzalone, Andrew V.; Petrusich, Alexandria; Osuna, Christa E.; O’Malley, Tiernan T.; Stewart-Ornstein, Jacob; Heath, Jack M.; Nehilla, Barrett J.; Asmal, Mohammed; Malech, Harry L.

Abstract
Chronic granulomatous disease (CGD) is a severe monogenic immunodeficiency caused by damaging variants in genes required for microbicidal NADPH oxidase activity. Autosomal recessive p47phox-deficient CGD (p47-CGD) is predominantly caused by a two-nucleotide deletion in exon 2 (delGT) of NCF1.

We developed PM359, an autologous CD34+ hematopoietic stem-cell therapy in which prime editing is used to correct delGT. Two participants received PM359 after myeloid conditioning with busulfan: neutrophils and platelets engrafted promptly in both patients.

Adverse events were consistent with myeloid conditioning with busulfan. NADPH oxidase activity was observed in neutrophils within 1 month and was maintained for 6 months and 4 months as of the last follow-up visit in Participants 1 and 2, respectively.

These results support further investigation of prime editing of CD34+ cells to treat p47-CGD.

(Funded by Prime Medicine; ClinicalTrials.gov number, NCT06559176.)
Web | DOI | New England Journal of Medicine
 
Back
Top Bottom